Ganoderma lucidum has several therapeutic effects, which include; antidiabetic, antihypertensive, antilipidemic, antioxidant, and many more. This study evaluates the anti-endocrine investigation of G. lucidum in streptozotocin-induced diabetic rats. Antidiabetic properties of a modified streptozotocin-induced hyperglycemic model were used. Wistar rats were divided into six groups (n=5). All groups except normal control were induced with streptozotocin (50 mg/kg). Graded doses (30, 50, and 100 mg/kg) of G. lucidum methanol extract and 10 mg/kg glibenclamide were administered for 14 days. Blood glucose was monitored on Days 1, 7, and 14. Blood and tissue samples were analyzed for biochemical and histopathological screening. The anti-endocrine property showed a significant increase in the body weight and HDL (14.99) with an decrease in blood glucose level (day 0= 199.5, 7= 79.00 and 14= 56.00), total cholesterol (73.76), triglycerides (199.30) and LDL level (47.30), ALT (24.48), AST (43.86), ALP (13.36), GGC (0.53), TP (12.72), urea (28.78), creatinine (0.25), sodium (94.69) when compared with the control. A significant decrease in the pancreas and live weight with normal architectural functioning of the organs treated groups when compared with the control. These findings elicited G. lucidum elicited antidiabetic properties.
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Biotechnology |
| Journal Section | Research Article |
| Authors | |
| Publication Date | January 11, 2026 |
| Published in Issue | Year 2026 Volume: 30 Issue: 1 |